Sunscreen and visible light: what the evidence supports for hyperpigmentation

Sunscreen is the best-evidenced component of any routine for post-inflammatory hyperpigmentation, and the reason is not subtle: it removes the trigger that keeps the pigment responding.

What the systematic reviews recommend

SPF30+ broad-spectrum sunscreen was recommended in almost every high-quality study of post-inflammatory hyperpigmentation treatment. Topical retinoids, hydroxy acids and broad-spectrum sunscreen carried the greatest evidence support in the fetched systematic review of PIH treatment evidence.

Note what that review is and is not. It documented evidence for a set of treatments; the full-text algorithms were not extracted in the research session, so it is not a treatment protocol and should not be read as one. Retinoid and hydroxy-acid products carry real evidence at the ingredient level, which is a different thing from evidence for any particular product you can buy — including the ones listed in our product library.

The part sunscreen usually misses: visible light

Visible light is a significant and underrecognised contributor to hyperpigmentation. Visible light is particularly relevant to darker phototypes.

This is the part of the picture that a conventional white sunscreen does not address. UV filtering is not the same thing as visible-light protection, and for darker skin tones the difference between those two things is not academic.

What tinted sunscreen changes — and what the labels do not tell you

The mechanism under investigation is iron oxide, the pigment family that gives tinted sunscreens their tint and gives them visible-light protection. The problem is disclosure.

In an analysis of 37 tinted sunscreens, 97.3% did not list iron-oxide content as an active ingredient. Only 9.6% of responding brands disclosed iron-oxide percentages.

A tinted product that does not declare its iron-oxide content has not given you the information to judge whether it offers meaningful visible-light protection. In our product library, listings carry a provenance label and the date the price and availability were last checked — a verified listing tells you what a product cost at a retailer on a given day. It does not tell you whether that product protects against visible light, and we do not present it as if it did.

The strongest piece of evidence, and its limit

In a randomised trial of 68 patients with melasma, in which both arms used 4% hydroquinone, iron-oxide sunscreen outperformed UV-only sunscreen by 15% MASI improvement.

That result is worth reading carefully, because the caveat is not small. Both arms were on 4% hydroquinone — a prescription-strength treatment requiring medical supervision. The trial was in melasma, not untreated post-inflammatory hyperpigmentation. It therefore does not prove the same outcome for PIH, and it does not prove the same outcome for any commercial product on sale today. We report it because it is real, and we mark its limits because they are real too.

Hydroquinone 4%, topical retinoids and prescription azelaic acid 20% all require appropriate medical supervision. They are not routine first-line recommendations, and a dermatologist should be involved in any decision to use them.

A practical summary

Broad-spectrum SPF30+ or higher is the intervention with the broadest and strongest evidence behind it, and it is the one with the fewest caveats. Visible light is a documented contributor to hyperpigmentation, particularly in darker phototypes, and protection against it is worth considering — but the labelling data above shows that you often cannot tell from a product's ingredient list whether a tinted sunscreen contains iron oxides at all. Where a product's iron-oxide content is not disclosed, treat it as unverified rather than assuming protection.

Seek medical evaluation for worsening melasma, post-inflammatory hyperpigmentation that has not responded after three to six months of consistent care, and anything suspected to be skin cancer.